Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Halozyme Therapeutics logo
$91.35 -1.69 (-1.82%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$94.82 +3.47 (+3.80%)
As of 11/20/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Advanced

Key Stats

Today's Range
$90.79
▼
$93.64
50-Day Range
$91.35
▼
$131.18
52-Week Range
$61.22
▼
$134.00
Volume
1.50 million shs
Average Volume
2.30 million shs
Market Capitalization
$10.41 billion
P/E Ratio
23.24
Dividend Yield
N/A
Price Target
$110.17
Consensus Rating
Hold

Company Overview

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners. Its work centers on making selected injectable treatments available through alternative routes of administration.

AI Generated. May Contain Errors.

Halozyme Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

HALO MarketRank™: 
4.539464460955 of 5 stars

Halozyme Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 29th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Halozyme Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Halozyme Therapeutics has a consensus price target of $110.17, representing about 20.6% upside from its current price of $91.35.

  • Amount of Analyst Coverage

    Halozyme Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Halozyme Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Halozyme Therapeutics are expected to grow by 17.51% in the coming year, from $8.34 to $9.80 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Halozyme Therapeutics is 23.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.19.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Halozyme Therapeutics is 23.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.

  • Price to Earnings Growth Ratio

    Halozyme Therapeutics has a PEG Ratio of 0.34. PEG Ratios below 1 indicate that a company could be undervalued.

  • Percentage of Shares Shorted

    12.28% of the float of Halozyme Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Halozyme Therapeutics has a short interest ratio ("days to cover") of 6.81.
  • Change versus previous month

    Short interest in Halozyme Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving.
  • Dividend Yield

    Halozyme Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Halozyme Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Halozyme Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Halozyme Therapeutics this week, compared to 8 articles on an average week.
  • Search Interest

    Only 14 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,744,643.00 in company stock.

  • Percentage Held by Insiders

    2.50% of the stock of Halozyme Therapeutics is held by insiders.

  • Percentage Held by Institutions

    97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Halozyme Therapeutics' insider trading history.
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HALO Stock News Headlines

Halozyme Therapeutics (NASDAQ:HALO) Earns "Buy" Rating from HC Wainwright
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Headlines

HALO Stock Analysis - Frequently Asked Questions

Halozyme Therapeutics' stock was trading at $67.30 at the start of the year. Since then, HALO stock has increased by 35.7% and is now trading at $91.35.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.09. The company's revenue was up 39.1% on a year-over-year basis.
Read the conference call transcript
.

Halozyme Therapeutics subsidiaries include these companies: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

Halozyme Therapeutics' top institutional investors include Boston Partners (2.42%), Congress Asset Management Co. (2.01%), Groupama Asset Managment (1.67%) and First Trust Advisors LP (1.59%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, Mahesh Krishnan, Cortney Caudill and Cortney Caudill.
View institutional ownership trends
.

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), Gilead Sciences (GILD), Intel (INTC), Palantir Technologies (PLTR) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/05/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HALO
CIK
1159036
Employees
423
Year Founded
1998

Price Target and Rating

High Price Target
$149.00
Low Price Target
$56.00
Potential Upside/Downside
+20.6%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.93
Trailing P/E Ratio
23.24
Forward P/E Ratio
9.32
P/E Growth
0.34
Net Income
$316.89 million
Net Margins
26.93%
Pretax Margin
36.34%
Return on Equity
751.81%
Return on Assets
23.84%

Debt

Debt-to-Equity Ratio
13.50
Current Ratio
3.88
Quick Ratio
3.60

Sales & Book Value

Annual Sales
$1.40 billion
Price / Sales
7.46
Cash Flow
$4.77 per share
Price / Cash Flow
19.15
Book Value
($0.48) per share
Price / Book
-190.31

Miscellaneous

Outstanding Shares
114,010,000
Free Float
111,160,000
Market Cap
$10.41 billion
Optionable
Optionable
Beta
0.92

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:HALO) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners